Cantor Fitzgerald Boosts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $211.00

Sarepta Therapeutics (NASDAQ:SRPT) had its price target raised by Cantor Fitzgerald from $175.00 to $211.00 in a research note issued to investors on Friday, BenzingaRatingsTable reports. The firm currently has an overweight rating on the biotechnology company’s stock.

SRPT has been the subject of several other reports. Oppenheimer restated a hold rating on shares of Sarepta Therapeutics in a report on Tuesday, October 8th. HC Wainwright set a $160.00 target price on Sarepta Therapeutics and gave the company a buy rating in a report on Friday, September 13th. Leerink Swann restated an outperform rating and issued a $216.00 target price (up from $186.00) on shares of Sarepta Therapeutics in a report on Friday. Royal Bank of Canada restated an outperform rating and issued a $215.00 target price on shares of Sarepta Therapeutics in a report on Friday. Finally, Morgan Stanley dropped their target price on Sarepta Therapeutics from $220.00 to $160.00 and set an overweight rating for the company in a report on Friday, October 11th. Two analysts have rated the stock with a hold rating, twenty-two have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $197.89.

NASDAQ:SRPT traded up $31.58 during trading hours on Friday, hitting $132.05. The company had a trading volume of 10,757,149 shares, compared to its average volume of 1,071,850. The company has a current ratio of 6.31, a quick ratio of 5.54 and a debt-to-equity ratio of 0.49. The company has a 50-day moving average of $100.19 and a 200 day moving average of $111.02. The company has a market cap of $7.56 billion, a P/E ratio of -24.18 and a beta of 2.30. Sarepta Therapeutics has a 1 year low of $72.05 and a 1 year high of $158.80.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Thursday, November 7th. The biotechnology company reported ($1.70) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.35) by ($0.35). The company had revenue of $99.04 million during the quarter, compared to analysts’ expectations of $98.49 million. Sarepta Therapeutics had a negative net margin of 169.87% and a negative return on equity of 55.44%. The firm’s quarterly revenue was up 26.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.15) earnings per share. On average, analysts forecast that Sarepta Therapeutics will post -6.02 earnings per share for the current year.

In other news, EVP David T. Howton sold 25,000 shares of the company’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $105.00, for a total value of $2,625,000.00. Following the transaction, the executive vice president now owns 24,388 shares of the company’s stock, valued at approximately $2,560,740. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 6.60% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Janney Montgomery Scott LLC lifted its stake in Sarepta Therapeutics by 2.7% during the 2nd quarter. Janney Montgomery Scott LLC now owns 4,078 shares of the biotechnology company’s stock worth $620,000 after acquiring an additional 109 shares in the last quarter. ETRADE Capital Management LLC lifted its stake in Sarepta Therapeutics by 5.2% during the 2nd quarter. ETRADE Capital Management LLC now owns 3,107 shares of the biotechnology company’s stock worth $472,000 after acquiring an additional 153 shares in the last quarter. Coastal Investment Advisors Inc. lifted its stake in Sarepta Therapeutics by 57.4% during the 2nd quarter. Coastal Investment Advisors Inc. now owns 425 shares of the biotechnology company’s stock worth $64,000 after acquiring an additional 155 shares in the last quarter. US Bancorp DE lifted its stake in Sarepta Therapeutics by 16.1% during the 2nd quarter. US Bancorp DE now owns 1,193 shares of the biotechnology company’s stock worth $181,000 after acquiring an additional 165 shares in the last quarter. Finally, MML Investors Services LLC lifted its stake in Sarepta Therapeutics by 8.1% during the 2nd quarter. MML Investors Services LLC now owns 2,230 shares of the biotechnology company’s stock worth $339,000 after acquiring an additional 167 shares in the last quarter. 97.78% of the stock is currently owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Read More: Euro STOXX 50 Index

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit